



## Influenza Vaccination for People with Chronic Diseases

Guest Editors:

**Prof. Dr. Ju-Chi Liu**

Division of Cardiology,  
Department of Internal Medicine,  
Shuang Ho Hospital, Taipei  
Medical University, Taipei City,  
Taiwan

**Dr. Wen-Rui Hao**

Division of Cardiology,  
Department of Internal Medicine,  
Shuang Ho Hospital, Taipei  
Medical University, New Taipei  
City, Taiwan

**Dr. Chun-Chao Chen**

Division of Cardiology,  
Department of Internal Medicine,  
Shuang Ho Hospital, Taipei  
Medical University, New Taipei  
City, Taiwan

### Message from the Guest Editors

The effect of influenza vaccination on decreasing the risk of influenza virus infection has been well reported before. Moreover, via the protection from the influenza vaccine, the risk of mortality and other complications of influenza virus infection could be significantly lowered. Therefore, it is highly recommended to receive the influenza vaccine annually, especially for high-risk populations such as patients with chronic diseases, the elderly, and healthcare providers. In addition to the protective effect from infection, the other potential benefits of influenza vaccination have also been demonstrated in previous research. However, detailed mechanism and clinical data on the additional effects of influenza vaccination among patients with chronic diseases are still lacking.

We are pleased to invite you to submit research articles regarding the effectiveness and potential mechanism of the influenza vaccine among patients with chronic diseases. Clinical observational studies, randomized control trials, and basic molecular/animal investigation are all welcome for submission.

Deadline for manuscript  
submissions:

**closed (25 May 2023)**





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)